Last reviewed · How we verify
Sacituzumab Govitecan (SG)
Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2 on cancer cells and delivers the topoisomerase I inhibitor SN-38 directly to tumor tissue.
Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2 on cancer cells and delivers the topoisomerase I inhibitor SN-38 directly to tumor tissue. Used for Metastatic triple-negative breast cancer, Metastatic urothelial carcinoma, Non-small cell lung cancer.
At a glance
| Generic name | Sacituzumab Govitecan (SG) |
|---|---|
| Also known as | Trodelvy®, GS-0132, IMMU 132, Trodelvy, IMMU-132 |
| Sponsor | University of California, Irvine |
| Drug class | Antibody-drug conjugate (ADC) |
| Target | Trop-2 (TACSTD2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The drug consists of a humanized monoclonal antibody against Trop-2 (a tumor-associated antigen) conjugated to govitecan, which is metabolized to SN-38, a potent topoisomerase I inhibitor. Upon binding to Trop-2 on cancer cell surfaces, the antibody-drug conjugate is internalized, releasing SN-38 intracellularly to induce DNA damage and apoptosis. This targeted delivery approach aims to maximize efficacy while reducing systemic toxicity compared to unconjugated chemotherapy.
Approved indications
- Metastatic triple-negative breast cancer
- Metastatic urothelial carcinoma
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea
- Fatigue
- Anemia
Key clinical trials
- Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer (PHASE1, PHASE2)
- Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC (PHASE2)
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (PHASE3)
- Study of Novel Treatment Combinations in Patients With Lung Cancer (PHASE2)
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread (PHASE2)
- Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer (PHASE1)
- A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) (PHASE2)
- Saci Nivo Rela for TNBC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sacituzumab Govitecan (SG) CI brief — competitive landscape report
- Sacituzumab Govitecan (SG) updates RSS · CI watch RSS
- University of California, Irvine portfolio CI